The wide variability of perospirone metabolism and the effect of perospirone on prolactin in psychiatric patients

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 6, 2010, Pages 830-833

  Suzuki, Yutaro ^a   Sawamura, Kazushi ^a   Ono, Shin ^a   Fukui, Naoki ^a   Sugai, Takuro ^a   Watanabe, Junzo ^a   Tsuneyama, Nobuto ^a   Inoue, Yoshimasa ^b   Someya, Toshiyuki ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b MP Technopharma Corporation Technology Department   (Japan)

Author keywords

Dopamine D2; ID15036; Perospirone; Plasma concentration; Prolactin

Indexed keywords

BENZODIAZEPINE DERIVATIVE; DOPAMINE 2 RECEPTOR; DRUG METABOLITE; ID 15036; N [4 [4 (1,2 BENZISOTHIAZOL 3 YL) 1 PIPERAZINYL]BUTYL] 1 HYDROXY 1,2 CYCLOHEXANEDICARBOXIMIDE; PEROSPIRONE; PROLACTIN; UNCLASSIFIED DRUG; HYDROXYPEROSPIRONE; INDOLE DERIVATIVE; ISOINDOLE DERIVATIVE; NEUROLEPTIC AGENT; THIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DOPAMINE RECEPTOR BLOCKING; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; FEMALE; HUMAN; HYPERPROLACTINEMIA; MALE; MONOTHERAPY; PROLACTIN BLOOD LEVEL; SCHIZOPHRENIA; BLOOD; ENZYME IMMUNOASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INDIVIDUALITY; MIDDLE AGED;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INDIVIDUALITY; INDOLES; ISOINDOLES; MALE; MIDDLE AGED; PROLACTIN; SCHIZOPHRENIA; THIAZOLES;

EID: 77955056192     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.03.027     Document Type: Article

References (21)

1. de Paulis T. Perospirone (Sumitomo Pharmaceuticals). Curr Opin Investig Drugs 2002, 3:121-129.
2. Dorne J.L., Walton K., Renwick A.G. Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment. Food Chem Toxicol 2003, 41:201-224.
3. Franz A.G. Prolactin. N Engl J Med 1978, 198:201-207.
4. Haddad P.M., Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004, 64:2291-2314.
5. Hikida K., Inoue Y., Miyazaki T., Kojima N., Ohkura Y. Determination of bromperidol in serum by automated column-switching high-performance liquid chromatography. J Chromatogr 1989, 495:227-234.
6. Hirose A., Kato T., Ohno Y., Shimizu H., Tanaka H., Nakamura M., et al. Pharmacological actions of SM-9018, a new neuroleptic drug with both potent 5-hydroxytryptamine2 and dopamine2 antagonistic actions. Jpn J Pharmacol 1990, 53:321-329.
7. Kapur S., Zipursky R., Jones C., Remington G., Houle S. Relationship between dopamine D (2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000, 157:514-520.
8. Kinon B.J., Gilmore J.A., Liu H., Halbreich U.M. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 2003, 28:55-68.
9. Kitamura A., Mizuno Y., Natsui K., Yabuki M., Komuro S., Kanamaru H. Characterization of human cytochrome P450 enzymes involved in the in vitro metabolism of perospirone. Biopharm Drug Dispos 2005, 26:59-65.
10. Kleinberg D.L., Davis J.M., de Coster R., Van Baelen B., Brecher M. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol. 1999, 19:57-61.
11. Knegtering R., Baselmans P., Castelein S., Bosker F., Bruggeman R., van den Bosch R.J. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry 2005, 162:1010-1012.
12. Lee B.H., Kim Y.K. The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:658-662.
13. Marken P.A., Haykal R.F., Fisher J.N. Management of psychotropic-induced hyperprolactinemia. Clin Pharm 1992, 11:851-856.
14. Melkersson K.I. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Hum Psychopharmacol 2006, 21:529-532.
15. Molitch M.E. Prolactin. The pituitary 1995, 136-186. Blackwell Science, Cambridge MA. S. Melmed (Ed.).
16. Onrust S.V., McClellan K. Perospirone. CNS Drugs 2001, 15:329-337.
17. Ozdemir V., Kalow W., Tang B.K., Paterson A.D., Walker S.E., Endrenyi L., et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 2000, 10:373-388.
18. Takahashi Y., Kusumi I., Ishikane T., Koyama T. In vivo occupation of dopamine D1, D2 and serotonin(2A) receptors by novel antipsychotic drug, SM-9018 and its metabolite, in rat brain. J Neural Transm 1998, 105:181-191.
19. Togo T., Iseki E., Shoji M., Oyama I., Kase A., Uchikado H., et al. Prolactin levels in schizophrenic patients receiving perospirone in comparison to risperidone. J Pharmacol Sci 2003, 91:259-262.
20. Volavka J., Czobor P., Cooper T.B., Sheitman B., Lindenmayer J.P., Citrome L., et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry 2004, 65:57-61.
21. Yasui-Furukori N., Inoue Y., Tateishi T. Determination of a new atypical antipsychotic agent perospirone and its metabolite in human plasma by automated column-switching high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2003, 789:239-245.